812 results on '"Gisselbrecht, C."'
Search Results
2. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
3. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
4. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
5. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study
6. Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphoma
7. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin’s disease
8. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
9. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
10. Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy
11. Lymphome T périphérique : nouvelles substances adaptées à l’histologie ?
12. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
13. How to define intermediate stage in Hodgkinʼs lymphoma?
14. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab
15. Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
16. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study
17. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
18. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas
19. Reducing Bureaucracy in Clinical Research: A Call for Action
20. Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial
21. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma
22. In vivo purging and relapse prevention following ASCT
23. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies
24. Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients
25. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study
26. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins’s disease or non-Hodgkin’s lymphoma
27. Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent
28. Intensification thérapeutique et autogreffe de cellules souches hématopoïétiques (CSH) dans le traitement des cancers du sein métastatiques : résultats du programme national Pegase 04
29. Alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European mantle cell lymphoma network (MCL net): V116
30. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry
31. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas
32. Comparison between autologous and allogeneic stem cell transplantation in patients with relapsing follicular lymphoma: use of the Propensity Score to reduce recruitment bias in observational studies: O260
33. Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II and IIIA)
34. Peripheral blood stem cell CD34+ autologous transplant in relapsed follicular lymphoma
35. Autologous stem cell transplantation in aggressive non-Hodgkin’s lymphoma
36. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2–3 diffuse large B-cell lymphoma
37. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study
38. Managing large cell lymphoma
39. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
40. How to define intermediate stage in Hodgkinʼs lymphoma?
41. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe dʼEtude des Lymphomes de lʼAdulte
42. 17. Paediatric Lymphomas: 085 THE 15–20 YEAR OLD PATIENTS WITH NHL TREATED IN FRANCE: DATA OF CHILDHOOD AND ADULT DATABASES
43. 15. Clinical Results in Lymphoma II: 070 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS-RELATED LYMPHOMA WITH RISK-ADAPTED INTENSIVE CHEMOTHERAPY: FINAL ANALYSIS OF THE NHL-HIV 93 TRIAL BY THE GELA-GICAT INTERGROUP
44. 15. Clinical Results in Lymphoma II: 066 AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) AS CONSOLIDATION CHEMOTHERAPY (CT) FOR PATIENTS (PTS) WITH LOW-INTERMEDIATE (LI) RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND OVEREXPRESSION OF BCL2 PROTEIN. RESULTS OF THE GELA TRIAL LNH98-B2
45. Impact of high-dose therapy on the course of indolent lymphoma. A study considering patient as his own control
46. Lymphomes non hodgkiniens T et NK périphériques
47. Prognostic Factors in Patients With Aggressive Non-Hodgkinʼs Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe dʼEtude des Lymphomes de lʼAdulte
48. Rituximab versus nothing after high-dose consolidative first-line chemotherapy with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma. Results of the first interim analysis of the randomised LNH98-B3 GELA study
49. Ifosfamide salvage treatment before autologous stem cell transplantation in patients with refractory and relapsed Hodgkinʼs lymphoma: a GELA experience
50. Hodgkinʼs lymphoma: what is next in salvage treatment?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.